147 related articles for article (PubMed ID: 3319277)
1. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
Gaver RC; George AM; Deeb G
Cancer Chemother Pharmacol; 1987; 20(4):271-6. PubMed ID: 3319277
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.
Gaver RC; Deeb G
Cancer Chemother Pharmacol; 1986; 16(3):201-6. PubMed ID: 3516429
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate.
Duncan GF; Faulkner HC; Farmen RH; Pittman KA
J Pharm Sci; 1988 Mar; 77(3):273-6. PubMed ID: 3286860
[TBL] [Abstract][Full Text] [Related]
4. The disposition of carboplatin in the beagle dog.
Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH
Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
Cho YB; Kim KH; Kim DK
Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
[TBL] [Abstract][Full Text] [Related]
7. The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin.
Dible SE; Siddik ZH; Harrap KR
Cancer Chemother Pharmacol; 1988; 22(1):11-6. PubMed ID: 3293838
[TBL] [Abstract][Full Text] [Related]
8. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
[TBL] [Abstract][Full Text] [Related]
9. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
Zucca E; Cattaneo MT; Cavalli F; Guaitani A; Filipazzi V; Bartosek I
G Ital Chemioter; 1985; 32(1):25-8. PubMed ID: 3913618
[No Abstract] [Full Text] [Related]
11. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
12. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
13. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
15. Biotransformations of oxaliplatin in rat blood in vitro.
Luo FR; Wyrick SD; Chaney SG
J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro.
Cohen JD; Robins HI
Cancer Res; 1987 Aug; 47(16):4335-7. PubMed ID: 3300964
[TBL] [Abstract][Full Text] [Related]
17. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.
Maruhn D; Siefert HM; Weber H; Rämsch K; Suwelack D
Arzneimittelforschung; 1985; 35(12):1781-6. PubMed ID: 4096729
[TBL] [Abstract][Full Text] [Related]
19. A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates.
Bullen WW; Andress LD; Chang T; Whitfield LR; Welch ML; Newman RA
Cancer Chemother Pharmacol; 1992; 30(3):193-8. PubMed ID: 1628368
[TBL] [Abstract][Full Text] [Related]
20. Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia.
Cohen JD; Robins HI; Schmitt CL; Tanner MA
Cancer Res; 1989 Nov; 49(21):5805-9. PubMed ID: 2676150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
